All In Biotech

Drug Trial Radar · NCT04480762

A Trial of SHR-1703 in Healthy Adults

A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1703 Injection Administered Subcutaneously in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Aug 4, 2020

Primary completion

Sep 21, 2021

Study completion Sep 21, 2021

Sponsor

Sponsor type
Industry
First posted
Jul 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in Healthy subjects. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose SHR-1703 administered subcutaneously in Chinese healthy subjects.

Conditions

  • Asthma

Interventions

  • SHR-1703Drug

    SHR-1703

  • PlaceboDrug

    Placebo of the SHR-1703

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse events (AEs) and serious adverse events (SAEs)Time frame: From Day 1 to Days 155
  2. Safety as determined by abnormality in haematologyTime frame: From Day 1 to Days 155
  3. Safety as determined by abnormality in clinical chemistryTime frame: From Day 1 to Days 155
  4. Safety as determined by abnormality in urinalysisTime frame: From Day 1 to Days 155
  5. Safety as determined by evaluation of blood pressure in mmHgTime frame: From Day 1 to Days 155
  6. Safety as determined by evaluation of Pulse rate in beats per minuteTime frame: From Day 1 to Days 155
  7. Safety as determined by evaluation of body temperature in degree CelsiusTime frame: From Day 1 to Days 155
  8. Safety as determined by evaluation of Respiratory rate in beats per minuteTime frame: From Day 1 to Days 155
  9. Safety as determined by analysis of 12-lead ECG variables: heart rate (beats per minute)Time frame: From Day 1 to Days 155
  10. Safety as determined by analysis of 12-lead ECG variables: PR, QRS, QT and QTcF (milliseconds)Time frame: From Day 1 to Days 155

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.